AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23572466 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of VLNTX and clonidine
Number of subjects: 174
Study 23572466 — intervention group
Group type: EXPERIMENTAL
Intervention: In-treatment smokers (n = 96)
Number of subjects: 174
Study 23572466 — intervention group
Group type: COMPARATOR
Intervention: Smokers not allowed to smoke (n = 45) or nonsmokers (n = 33)
Number of subjects: 174
Study 21241167 — intervention group
Group type: EXPERIMENTAL
Intervention: New sanitary pad with a non-woven specially-shaped surface top sheet
Number of subjects: 21
Study 21241167 — intervention group
Group type: COMPARATOR
Intervention: Conventional sanitary pad with a perforated film top sheet
Number of subjects: 21
Study 19597420 — intervention group
Group type: EXPERIMENTAL
Intervention: Early administration of rhG‐CSF (4th day)
Number of subjects: 48
Study 19597420 — intervention group
Group type: COMPARATOR
Intervention: Late administration of rhG‐CSF (7th day)
Number of subjects: 48
Study 17368530 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic care (HC: individual homeopathic consultations with any homeopathic medicine in any potency being prescribed)
Number of subjects: 208
Study 17368530 — intervention group
Group type: COMPARATOR
Intervention: Self-prescribed homeopathic medicine (SPH) in C-30 administered twice weekly for 12 weeks
Number of subjects: 208
Study 17368530 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic care (HC)
Number of subjects: 208
Study 17368530 — intervention group
Group type: COMPARATOR
Intervention: Self-prescribed homeopathic medicine (SPH)
Number of subjects: 208
Study 15353916 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) administered subcutaneously in a fixed daily dose
Number of subjects: 38
Study 15353916 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral anticoagulant therapy (OAT)
Number of subjects: 38
Study 11150937 — intervention group
Group type: EXPERIMENTAL
Intervention: Male bodybuilders
Number of subjects: 88
Study 11150937 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with eating disorders
Number of subjects: 88
Study 11150937 — intervention group
Group type: COMPARATOR
Intervention: Control men
Number of subjects: 88
Study 11150937 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodybuilders and men with eating disorders
Number of subjects: 88
Study 9245865 — intervention group
Group type: EXPERIMENTAL
Intervention: DIEP flap
Number of subjects: 18
Study 9245865 — intervention group
Group type: COMPARATOR
Intervention: TRAM flap
Number of subjects: 18
Study 9245865 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 8490638 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group psychotherapy with emphasis on abstinence (high and low)
Number of subjects: 143
Study 8490638 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group psychotherapy with treatment intensity (high and low)
Number of subjects: 143
Study 3318194 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile extract
Number of subjects: 14
Study 30234480 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing frames
Number of subjects: 585
Study 26559192 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft wrap and buddy taping (SW)
Number of subjects: 68
Study 26559192 — intervention group
Group type: COMPARATOR
Intervention: Reduction and cast (RC)
Number of subjects: 68
Study 24888929 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral feeding (liquid diets commenced 2 hours after surgery)
Number of subjects: 140
Study 24888929 — intervention group
Group type: COMPARATOR
Intervention: Delayed oral feeding (liquid diets commenced 8 hours after surgery)
Number of subjects: 140
Study 22734372 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle-tension-balance acupuncture (group A)
Number of subjects: 70
Study 22734372 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture (group B)
Number of subjects: 70
Study 20721460 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 50
Study 20721460 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia plus sedation
Number of subjects: 50
Study 18509207 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-wave (DW) bolus (50:50% over 2 h) before low-GI meals
Number of subjects: 20
Study 18509207 — intervention group
Group type: COMPARATOR
Intervention: Standard bolus (100%) before low-GI meals
Number of subjects: 20
Study 18509207 — intervention group
Group type: EXPERIMENTAL
Intervention: High-GI meals (regardless of bolus type)
Number of subjects: 20
Study 16029698 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-second application of sodium hydroxide
Number of subjects: 66
Study 16029698 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-minute application of sodium hydroxide
Number of subjects: 66
Study 16029698 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-minute application of sodium hydroxide
Number of subjects: 66
Study 12217455 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose alcohol
Number of subjects: 132
Study 12217455 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose alcohol
Number of subjects: 132
Study 12217455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 12217455 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 132
Study 10614903 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifluorid 12 (6% F)
Number of subjects: 8
Study 10614903 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat (2.26% F)
Number of subjects: 8
Study 10614903 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluor Protector (0.1% F)
Number of subjects: 8
Study 7863716 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin
Number of subjects: 10
Study 7863716 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 10
Study 1774568 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose warfarin (LDW)
Number of subjects: 95
Study 1774568 — intervention group
Group type: COMPARATOR
Intervention: Sequential compression devices (SCD)
Number of subjects: 95
Study 6124654 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 20 mg clorazepate dipotassium (CZP)
Number of subjects: 17
Study 6124654 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 20 mg clorazepate dipotassium (CZP)
Number of subjects: 17
Study 6124654 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 20 mg clorazepate dipotassium (CZP)
Number of subjects: 17
Study 30721093 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterned electrical neuromuscular stimulation (PENS)
Number of subjects: 21
Study 30721093 — intervention group
Group type: COMPARATOR
Intervention: Sham treatments
Number of subjects: 21
Study 27606700 — intervention group
Group type: EXPERIMENTAL
Intervention: Web- and text messaging-based intervention over 3 months
Number of subjects: 1041
Study 27606700 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (Control)
Number of subjects: 1041
Study 24279691 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac HPβCD SC
Number of subjects: 325
Study 24279691 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac HPβCD IM
Number of subjects: 325
Study 24279691 — intervention group
Group type: COMPARATOR
Intervention: Voltaren® IM
Number of subjects: 325
Study 24680796 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg daily for 8 weeks
Number of subjects: 13
Study 24680796 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 8 weeks
Number of subjects: 13
Study 24680796 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil during open-label use for an additional 8 weeks
Number of subjects: 13
Study 22775125 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring (CR) training aimed at decreasing emotional response to shock and conditioned stimuli.
Number of subjects: 0
Study 22775125 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CR training).
Number of subjects: 0
Study 19608808 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane 3%-8%
Number of subjects: 130
Study 19608808 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane 1%-3%
Number of subjects: 130
Study 19608808 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 130
Study 17379748 — intervention group
Group type: COMPARATOR
Intervention: Sedentary bed rest (Control, n = 8)
Number of subjects: 24
Study 17379748 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (n = 8)
Number of subjects: 24
Study 17379748 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein and BCAA supplementation (n = 8)
Number of subjects: 24
Study 15064594 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi practitioners
Number of subjects: 47
Study 15064594 — intervention group
Group type: EXPERIMENTAL
Intervention: Golfers
Number of subjects: 47
Study 15064594 — intervention group
Group type: COMPARATOR
Intervention: Elderly control subjects
Number of subjects: 47
Study 11707048 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized AV interval with rate adaptive AV interval shortening (optimized/R)
Number of subjects: 14
Study 11707048 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed AV interval = 150 ms with rate adaptation (150/R)
Number of subjects: 14
Study 11707048 — intervention group
Group type: COMPARATOR
Intervention: Fixed AV interval = 150 ms without rate adaptation (150/Fixed)
Number of subjects: 14
Study 11707048 — intervention group
Group type: COMPARATOR
Intervention: Least-favorable AV intervals
Number of subjects: 14
Study 9924274 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately-fatty breakfast (25.7 g fat; M)
Number of subjects: 24
Study 9924274 — intervention group
Group type: COMPARATOR
Intervention: Low-fat high-carbohydrate breakfast (5.5 g fat; L)
Number of subjects: 24
Study 8036679 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (15 mg/kg) plus artesunate (10 mg/kg)
Number of subjects: 552
Study 8036679 — intervention group
Group type: COMPARATOR
Intervention: High dose mefloquine (25 mg/kg)
Number of subjects: 552
Study 2847464 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,500 IU Logiparin
Number of subjects: 51
Study 2847464 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 IU per kg Logiparin
Number of subjects: 51
Study 2847464 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,500 IU Logiparin
Number of subjects: 51
Study 29676968 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose milk (120 mg/100 mL calcium, vitamin D3 30 UI/100 mL)
Number of subjects: 500
Study 29676968 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: milk (180 mg/100 mL calcium, 120 UI/100 mL vitamin D)
Number of subjects: 500
Study 29676968 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: milk (180 mg/100 mL calcium, 120 UI/100 mL vitamin D) and FOS (5 g/L)
Number of subjects: 500
Study 27380030 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of TAU
Number of subjects: 11
Study 27380030 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 11
Study 24530765 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain during infancy (from birth to 18 months of age)
Number of subjects: 379
Study 24530765 — intervention group
Group type: COMPARATOR
Intervention: Birth weight
Number of subjects: 379
Study 23312049 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (rosuvastatin + fenofibric acid)
Number of subjects: 2066
Study 20107154 — intervention group
Group type: EXPERIMENTAL
Intervention: LAL 2000 trial
Number of subjects: 46
Study 20107154 — intervention group
Group type: COMPARATOR
Intervention: 0496 study
Number of subjects: 46
Study 18756744 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-load bicycle exercise (FBE)
Number of subjects: 185
Study 18756744 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy only
Number of subjects: 185
Study 17086009 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance cardiography (ICG) care
Number of subjects: 0
Study 17086009 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 14506629 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (200 mg/d)
Number of subjects: 130
Study 14506629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 10641085 — intervention group
Group type: EXPERIMENTAL
Intervention: Trusopt + Xalatan (dorzolamide + latanoprost)
Number of subjects: 79
Study 8767437 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeping with the bed-head raised (15 cm)
Number of subjects: 0
Study 8767437 — intervention group
Group type: COMPARATOR
Intervention: Horizontal bed-head position
Number of subjects: 0
Study 8767437 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg twice a day) for group 3
Number of subjects: 0
Study 8767437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (30 mg) for group 2
Number of subjects: 0
Study 8767437 — intervention group
Group type: EXPERIMENTAL
Intervention: No drug therapy for group 1
Number of subjects: 0
Study 1717789 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockade
Number of subjects: 66
Study 1717789 — intervention group
Group type: COMPARATOR
Intervention: Independent type As
Number of subjects: 66
Study 1717789 — intervention group
Group type: COMPARATOR
Intervention: Dependent type As
Number of subjects: 66
Study 7069684 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to a clinical psychologist
Number of subjects: 239
Study 7069684 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to clinical psychologist)
Number of subjects: 239
Study 30266309 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT) with External Beam Radiation Therapy (EBRT)
Number of subjects: 432
Study 30266309 — intervention group
Group type: COMPARATOR
Intervention: Androgen Deprivation Therapy (ADT) alone
Number of subjects: 432
Study 29742190 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream-to-powder product
Number of subjects: 52
Study 27254283 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant, granisetron, and dexamethasone (AGD)
Number of subjects: 84
Study 27254283 — intervention group
Group type: COMPARATOR
Intervention: Palonosetron and dexamethasone (PD)
Number of subjects: 84
Study 24654454 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) for 12 weeks followed by endometrial curettage
Number of subjects: 10
Study 24654454 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) treatment
Number of subjects: 10
Study 22513154 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning resource focusing on pain assessment
Number of subjects: 42
Study 22513154 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning resource focusing on pharmacological management
Number of subjects: 42
Study 22513154 — intervention group
Group type: COMPARATOR
Intervention: Standard non-intervention group (n=164)
Number of subjects: 42
Study 20678687 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) tablet of glimepiride/metformin 2/500 mg
Number of subjects: 32
Study 20678687 — intervention group
Group type: COMPARATOR
Intervention: Separate tablets of glimepiride 2 mg + metformin 500 mg
Number of subjects: 32
Study 17723148 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention service consisting of consultations with a specialised nurse for the patient and their caregiver during the first three months after cardiac arrest.
Number of subjects: 0
Study 17723148 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 0
Study 17723148 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention service
Number of subjects: 0
Study 16027086 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 16027086 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40
Study 16027086 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cerebral injury)
Number of subjects: 40
Study 16027086 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral trauma patients
Number of subjects: 40
Study 12473010 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered Nurse (RN) turnover
Number of subjects: 2015
Study 12473010 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility characteristics (e.g., Medicare recipients, staffing levels, environmental quality)
Number of subjects: 2015
Study 12473010 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility characteristics (e.g., for-profit ownership, chain affiliation)
Number of subjects: 2015
Study 12473010 — intervention group
Group type: COMPARATOR
Intervention: Adjustment for resident characteristics (sex, age, race, education, marital status, morbid diagnoses, functional status)
Number of subjects: 2015
Study 12473010 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection
Number of subjects: 2015
Study 12473010 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization for infection
Number of subjects: 2015
Study 9627588 — intervention group
Group type: EXPERIMENTAL
Intervention: Family income (low vs affluent)
Number of subjects: 619
Study 9627588 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood income (poor/middle-affluent)
Number of subjects: 619
Study 9627588 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood income (middle-income)
Number of subjects: 619
Study 8552817 — intervention group
Group type: EXPERIMENTAL
Intervention: CT examination in ARDS patients
Number of subjects: 14
Study 8552817 — intervention group
Group type: COMPARATOR
Intervention: CT examination in normal subjects (control group)
Number of subjects: 14
Study 2298963 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis therapy
Number of subjects: 11
Study 2298963 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids and immunosuppressive drugs alone (Control)
Number of subjects: 11
Study 80682 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (60 mg daily for one week, 40 mg daily for four days, and then 30 mg daily for three days)
Number of subjects: 40
Study 80682 — intervention group
Group type: COMPARATOR
Intervention: Control (no steroid treatment)
Number of subjects: 40
Study 80682 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 40
Study 80682 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 30513485 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 27374276 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic MK-7 (180 µg)
Number of subjects: 20
Study 27374276 — intervention group
Group type: COMPARATOR
Intervention: Fermentation-derived MK-7 (90 µg)
Number of subjects: 20
Study 27374276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27374276 — intervention group
Group type: COMPARATOR
Intervention: Synthetic MK-7 (45 µg)
Number of subjects: 20
Study 27374276 — intervention group
Group type: COMPARATOR
Intervention: Synthetic MK-7 (90 µg)
Number of subjects: 20
Study 25686683 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 months of isoniazid preventive therapy (36IPT)
Number of subjects: 1995
Study 25686683 — intervention group
Group type: COMPARATOR
Intervention: 6 months of isoniazid preventive therapy (6IPT)
Number of subjects: 1995
Study 25686683 — intervention group
Group type: EXPERIMENTAL
Intervention: 36IPT
Number of subjects: 1995
Study 25686683 — intervention group
Group type: COMPARATOR
Intervention: 6IPT
Number of subjects: 1995
Study 25686683 — intervention group
Group type: EXPERIMENTAL
Intervention: 36IPT restricted to TST-positive participants
Number of subjects: 1995
Study 25686683 — intervention group
Group type: EXPERIMENTAL
Intervention: ART use
Number of subjects: 1995
Study 23073646 — intervention group
Group type: EXPERIMENTAL
Intervention: Online pre-screening survey
Number of subjects: 322
Study 23073646 — intervention group
Group type: COMPARATOR
Intervention: Phone screening
Number of subjects: 322
Study 21536199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS) therapy
Number of subjects: 75
Study 21536199 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy (control group)
Number of subjects: 75
Study 19711749 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16756421 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary payments contingent on demonstrating recent abstinence during the intervention week
Number of subjects: 88
Study 16756421 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐reinforcer magnitude condition
Number of subjects: 88
Study 16756421 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐reinforcer magnitude condition
Number of subjects: 88
Study 16756421 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent monetary payments during baseline weeks
Number of subjects: 88
Study 15614029 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (8 mug/kg per min)
Number of subjects: 41
Study 15614029 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose 5%)
Number of subjects: 41
Study 11391278 — intervention group
Group type: EXPERIMENTAL
Intervention: N-duopropenide alcohol solution (NDP)
Number of subjects: 69
Study 11391278 — intervention group
Group type: COMPARATOR
Intervention: Handwashing with nonantiseptic soap
Number of subjects: 69
Study 9014908 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PE) - five 50 mL/kg exchanges over 8-13 days
Number of subjects: 379
Study 9014908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin (IVIg) - Sandoglobulin, 0.4 g/kg daily for 5 days
Number of subjects: 379
Study 9014908 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (PE followed by IVIg)
Number of subjects: 379
Study 9014908 — intervention group
Group type: COMPARATOR
Intervention: Plasma Exchange (PE)
Number of subjects: 379
Study 9014908 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Immunoglobulin (IVIg)
Number of subjects: 379
Study 9014908 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment (PE + IVIg)
Number of subjects: 379
Study 8375422 — intervention group
Group type: EXPERIMENTAL
Intervention: Saruplase
Number of subjects: 0
Study 8375422 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 0